STEPHEN GEORGE DILLY
CIK 1389147 · See Remarks · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$10.98M
Companies
6
Total Filings
48
Lifetime Open-Market Net
-$21.65M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CDXS | See Remarks | 727,053 | $1.49 | $1.08M | -$151.3K | 11 | 2026-06-18 |
| Sierra Oncology, Inc. (SRRA) Delisted | CEO and President | 0 | $54.99 | $0 | $89.1K | 7 | 2022-07-01 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 15,000 | $0.18 | $2.7K | -$300.3K | 13 | 2020-06-03 |
| COLL | President and CEO | 370,297 | $26.73 | $9.90M | -$21.29M | 12 | 2018-06-13 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | See Remarks | 831,158 | — | — | $0 | 1 | 2016-02-26 |
| AVIGEN INC \DE (AVGN) Delisted | Director | — | — | — | $0 | 4 | 2009-12-21 |
Recent Filings · Page 3 of 5
48 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-03-20 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$20.3K | EDGAR |
| 2020-03-18 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Mixed | — | -$9.0K | EDGAR |
| 2019-06-12 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +2,500 | $0 | EDGAR |
| 2018-06-13 | COLL | Mixed | — | -$819.3K | EDGAR |
| 2018-06-12 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | +2,500 | $0 | EDGAR |
| 2018-06-08 | COLL | Mixed | — | -$2.93M | EDGAR |
| 2018-06-05 | COLL | Mixed | — | -$4.82M | EDGAR |
| 2017-10-25 | COLL | Sell (S) | −100,000 | -$3.35M | EDGAR |
| 2017-10-18 | COLL | Sell (S) | −1,154 | -$30.3K | EDGAR |
| 2017-10-06 | COLL | Sell (S) | −98,846 | -$2.59M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.